Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are Buying

Biohaven Ltd. (NYSE:BHVN) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 2, 2026, Citi analyst Samantha Semenkow raised the price target on Biohaven Ltd. (NYSE:BHVN) to $17 from $14 and maintained a Buy rating. Samantha Semenkow said the firm sees attractive risk/reward at current levels ahead of 2026 catalysts, noting recent competitor data in focal epilepsy are supportive of Biohaven’s Phase 3 opakalim trial expected to read out in the second half of 2026.

On March 19, 2026, Biohaven Ltd. (NYSE:BHVN) announced completion of enrollment in a Phase 2 proof-of-concept study for taldefgrobep alfa, a myostatin-activin pathway inhibitor aimed at weight loss in obesity, with topline data expected in the second half of 2026.

Earlier in March, Goldman Sachs raised its price target on Biohaven Ltd. (NYSE:BHVN) to $27 from $24 and maintained a Buy rating, citing positive Phase 3 results from Xenon’s azetukalner in focal onset seizures and viewing the data as supportive for the broader Kv7 class, including Biohaven’s opakalim.

Biohaven Ltd. (NYSE:BHVN) develops therapies across immunology, neuroscience, and oncology.

While we acknowledge the risk and potential of BHVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BHVN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.